表面活性蛋白 B 多态性（rs7316 和 rs1130866）及其与 COVID-19 疾病进展的相关性。

IF 3.7 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Cytokine Pub Date : 2024-10-04 DOI:10.1016/j.cyto.2024.156775

Amir Behrouzi , Fatemeh Sakhaee , Morteza Ghazanfari Jajin , Iraj Ahmadi , Enayat Anvari , Fattah Sotoodehnejadnematalahi , Abolfazl Fateh

{"title":"表面活性蛋白 B 多态性（rs7316 和 rs1130866）及其与 COVID-19 疾病进展的相关性。","authors":"Amir Behrouzi , Fatemeh Sakhaee , Morteza Ghazanfari Jajin , Iraj Ahmadi , Enayat Anvari , Fattah Sotoodehnejadnematalahi , Abolfazl Fateh","doi":"10.1016/j.cyto.2024.156775","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>It is critical to examine the pathogenic pathways in coronavirus disease 2019 (COVID-19) that resulted in the development of severe lung injury. Surfactant protein B (<em>SFTPB</em>) is a vital component for sustaining life and serves pivotal functions in the host’s defensive mechanisms and alveolar surface tension reduction. Our study aimed to determine the effect of <em>SFTPB</em> rs7316 and rs1130866 variants on the course of disease in COVID-19 patients.</div></div><div><h3>Methods</h3><div>The study cohort comprised 3,184 individuals diagnosed with COVID-19. We employed the RFLP approach to determine the variations of the <em>SFTPB</em> genes.</div></div><div><h3>Results</h3><div>SFTPB rs7316 did not exhibit a statistically significant correlation with COVID-19 mortality across different inheritance models. But, after making more changes for SARS-CoV-2 variants, it was found that there was a strong link between the TT and TC genotypes of <em>SFTPB</em> rs7316 and death rates, especially for the Delta variant. Furthermore, our study’s findings indicate a significant association between the <em>SFTPB</em> rs1130866 G allele and an elevated risk of mortality in COVID-19 across all variants of SARS-CoV-2.</div></div><div><h3>Conclusions</h3><div>The use of the SFTPB rs1130866 marker has the potential to facilitate the prediction of COVID-19 severity. On the other hand, for SFTPB rs7316, this kind of prediction seems to depend on the particular SARS-CoV-2 variants.</div></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"184 ","pages":"Article 156775"},"PeriodicalIF":3.7000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The surfactant protein B polymorphisms (rs7316 and rs1130866) and their correlation with disease progression of COVID-19\",\"authors\":\"Amir Behrouzi , Fatemeh Sakhaee , Morteza Ghazanfari Jajin , Iraj Ahmadi , Enayat Anvari , Fattah Sotoodehnejadnematalahi , Abolfazl Fateh\",\"doi\":\"10.1016/j.cyto.2024.156775\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>It is critical to examine the pathogenic pathways in coronavirus disease 2019 (COVID-19) that resulted in the development of severe lung injury. Surfactant protein B (<em>SFTPB</em>) is a vital component for sustaining life and serves pivotal functions in the host’s defensive mechanisms and alveolar surface tension reduction. Our study aimed to determine the effect of <em>SFTPB</em> rs7316 and rs1130866 variants on the course of disease in COVID-19 patients.</div></div><div><h3>Methods</h3><div>The study cohort comprised 3,184 individuals diagnosed with COVID-19. We employed the RFLP approach to determine the variations of the <em>SFTPB</em> genes.</div></div><div><h3>Results</h3><div>SFTPB rs7316 did not exhibit a statistically significant correlation with COVID-19 mortality across different inheritance models. But, after making more changes for SARS-CoV-2 variants, it was found that there was a strong link between the TT and TC genotypes of <em>SFTPB</em> rs7316 and death rates, especially for the Delta variant. Furthermore, our study’s findings indicate a significant association between the <em>SFTPB</em> rs1130866 G allele and an elevated risk of mortality in COVID-19 across all variants of SARS-CoV-2.</div></div><div><h3>Conclusions</h3><div>The use of the SFTPB rs1130866 marker has the potential to facilitate the prediction of COVID-19 severity. On the other hand, for SFTPB rs7316, this kind of prediction seems to depend on the particular SARS-CoV-2 variants.</div></div>\",\"PeriodicalId\":297,\"journal\":{\"name\":\"Cytokine\",\"volume\":\"184 \",\"pages\":\"Article 156775\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cytokine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1043466624002795\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466624002795","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：研究冠状病毒病 2019（COVID-19）导致严重肺损伤的致病途径至关重要。表面活性蛋白 B（SFTPB）是维持生命的重要成分，在宿主防御机制和降低肺泡表面张力方面发挥着关键作用。我们的研究旨在确定 SFTPB rs7316 和 rs1130866 变体对 COVID-19 患者病程的影响：研究队列包括 3,184 名确诊为 COVID-19 的患者。我们采用 RFLP 方法确定 SFTPB 基因的变异：结果：在不同的遗传模型中，SFTPB rs7316 与 COVID-19 死亡率的相关性没有统计学意义。但在对 SARS-CoV-2 变异进行更多改变后发现，SFTPB rs7316 的 TT 和 TC 基因型与死亡率之间存在密切联系，尤其是 Delta 变异。此外，我们的研究结果表明，在 COVID-19 中，SFTPB rs1130866 G 等位基因与 SARS-CoV-2 所有变异体的死亡风险升高之间存在显著关联：结论：使用 SFTPB rs1130866 标记有可能有助于预测 COVID-19 的严重程度。另一方面，对于 SFTPB rs7316，这种预测似乎取决于特定的 SARS-CoV-2 变体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The surfactant protein B polymorphisms (rs7316 and rs1130866) and their correlation with disease progression of COVID-19

Background

It is critical to examine the pathogenic pathways in coronavirus disease 2019 (COVID-19) that resulted in the development of severe lung injury. Surfactant protein B (SFTPB) is a vital component for sustaining life and serves pivotal functions in the host’s defensive mechanisms and alveolar surface tension reduction. Our study aimed to determine the effect of SFTPB rs7316 and rs1130866 variants on the course of disease in COVID-19 patients.

Methods

The study cohort comprised 3,184 individuals diagnosed with COVID-19. We employed the RFLP approach to determine the variations of the SFTPB genes.

Results

SFTPB rs7316 did not exhibit a statistically significant correlation with COVID-19 mortality across different inheritance models. But, after making more changes for SARS-CoV-2 variants, it was found that there was a strong link between the TT and TC genotypes of SFTPB rs7316 and death rates, especially for the Delta variant. Furthermore, our study’s findings indicate a significant association between the SFTPB rs1130866 G allele and an elevated risk of mortality in COVID-19 across all variants of SARS-CoV-2.

Conclusions

The use of the SFTPB rs1130866 marker has the potential to facilitate the prediction of COVID-19 severity. On the other hand, for SFTPB rs7316, this kind of prediction seems to depend on the particular SARS-CoV-2 variants.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cytokine 医学-免疫学

CiteScore

7.60

自引率

2.60%

发文量

262

审稿时长

48 days

期刊介绍： The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. * Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors. We will publish 3 major types of manuscripts: 1) Original manuscripts describing research results. 2) Basic and clinical reviews describing cytokine actions and regulation. 3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.